◀ Back to MAPK3
MAPK3 — SFN
Pathways - manually collected, often from reviews:
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
KSR/14-3-3 (dimer)/MEK1-2-active complex (KSR1-YWHAH_YWHAZ_YWHAQ_SFN_YWHAE_YWHAG_YWHAB-MAP2K1_MAP2K2)
(modification, collaborate)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
KSR/14-3-3 (dimer)/MEK1-2-active complex (KSR1-YWHAH_YWHAZ_YWHAQ_SFN_YWHAE_YWHAG_YWHAB-MAP2K1_MAP2K2)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, activates)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2-active (MAPK3/MAPK1)
→
RAF1/14-3-3 complex (RAF1-YWHAH_YWHAZ_YWHAQ_SFN_YWHAE_YWHAG_YWHAB)
(modification, activates)
Brummer et al., Oncogene 2003, Dougherty et al., Mol Cell 2005, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2-active (MAPK3/MAPK1)
→
RAF1/BRAF/14-3-3/14-3-3 complex (RAF1-BRAF-YWHAH_YWHAZ_YWHAQ_SFN_YWHAE_YWHAG_YWHAB)
(modification, activates)
Brummer et al., Oncogene 2003, Dougherty et al., Mol Cell 2005, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2-active (MAPK3/MAPK1)
→
BRAF/14-3-3 complex (BRAF-YWHAH_YWHAZ_YWHAQ_SFN_YWHAE_YWHAG_YWHAB)
(modification, activates)
Brummer et al., Oncogene 2003, Dougherty et al., Mol Cell 2005, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
Text-mined interactions from Literome
Schwab et al., Immunology 2008
(MAP Kinase Signaling System) :
Moreover,
SFN induced the expression of VDR, PPARgamma and phosphorylated ERK1/2 but did not
affect p38
MAPK activation
Pei et al., Toxicol Appl Pharmacol 2011
(Prostatic Neoplasms) :
Pre-treatment of PC-3 cells with methemoglobin decreased
SFN stimulated
MAPK activities
Xu et al., Anticancer Agents Med Chem 2012
(Neoplasms) :
NF-E2- related factor-2(Nrf-2), as well as
mitogen activated protein kinase ( MAPK ), is
regulated by
SFN